Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05199259 · ClinicalTrials.gov registry record
Multi-analyte Blood Test Clinical Trial
A clinical trial of Hepatocellular Carcinoma and Liver Cancer, sponsored by Helio Genomics.
- Recruiting
- Registry status
- 1,200
- Enrollment target
- 7
- Study locations
NCT05199259: Recruiting study of Hepatocellular Carcinoma and Liver Cancer, sponsored by Helio Genomics.
NCT05199259 is a study of Hepatocellular Carcinoma and Liver Cancer that is actively recruiting participants, run by Helio Genomics. The registered enrollment target is 1,200 participants, above the 249-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (382% higher). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05199259, a study of Hepatocellular Carcinoma and Liver Cancer, is actively recruiting participants, sponsored by Helio Genomics.
- RECRUITING
- Registry status
- 1,200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.
Primary Outcome
The primary objective is to measure the performance (sensitivity and specificity) the multi-analyte blood Test for the detection of liver cancers in high-risk particiapnats.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Multi-analyte Blood Test
Study Locations (7)
Texas
- South Texas Research Institute - Edinburg
- Texas Gastro Research - El Paso
- Impact Research Institute - Waco
California
- Providence Facey Medical Foundation - Mission Hills
Florida
- Guardian Angel Research Center - Tampa
Maryland
- GI Research Mercy Medical Center - Baltimore
Virginia
- Digestive & Liver Disease Specialist - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2025-03 |
What NCT05199259 shows while recruiting
NCT05199259 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 249-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (382% higher).
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Multi-analyte Blood Test is the first listed.
NCT05199259 lists 7 locations in 5 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05199259 about?
NCT05199259 is a clinical study titled "Multi-analyte Blood Test Clinical Trial". The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the He...
What is the current status of trial NCT05199259?
This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2022-03-01. Estimated completion is 2025-03.
What conditions does trial NCT05199259 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Liver Cirrhosis, HCC.
What interventions are being tested in trial NCT05199259?
The interventions under investigation include: Multi-analyte Blood Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05199259?
This trial is sponsored by Helio Genomics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05199259 being conducted?
This trial has 7 study locations across California, Florida, Maryland, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05199259's enrollment target sits among peer trials
1,200 8th of 145 higher than 138 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI